Navigation Links
The Leukemia & Lymphoma Society Offers Crucial Help at a Critical Time
Date:2/26/2008

LLS's Insurance Co-Pay Assistance Program Provides Financial Support for

Prescriptions, Health Insurance Co-Pays

WHITE PLAINS, N.Y., Feb. 26 /PRNewswire/ -- The lymphoma diagnosis was terrifying enough. But when Charlotte Kostakos, 75, and her husband, Steven, 74, began struggling with the spiraling costs of paying for her treatments, they were overwhelmed.

"As far as we're concerned our income is Social Security, period, and therefore we were extremely anxious," said Steven. Still reeling from the shock of learning that Charlotte had B-cell lymphoma, the Kostakos's, who live part of the year in Claremont, Fla., and the other half in Edgarton, Wis., couldn't imagine how they would manage the costs, even with Medicare coverage.

The Kostakos's turned to The Leukemia & Lymphoma Society's co-pay assistance program for help.

"I don't know where we'd be without this program -- it's been a huge help to us," Steven said. "Every little bit that we can get is a relief for us."

The program provides support for prescription drug co-pays and health insurance premiums for patients who meet certain income requirements. Since launching the program last year, LLS has expanded it to include more disease categories. The program currently covers patients with Hodgkin lymphoma, non- Hodgkin lymphoma, chronic lymphocytic leukemia, waldenstrom macroglobulinemia, acute myelogenous leukemia, myeloma and myelodysplastic syndromes.

Patients with private insurance, Medicare beneficiaries under Medicare Part B and/or Medicare Plan D, Medicare Supplementary Health Insurance and Medicare Advantage premium are eligible.

"Receiving a diagnosis of a blood cancer is overwhelming and that devastating news can be compounded by an inability to afford the treatments," said Anita Welborn, director, LLS's Information Resource Center, and administrator of the program. "LLS is trying to do what it can to help alleviate this burden for the neediest patients that it serves."

For more information, visit http://www.lls.org/copay or call 877-LLS-COPAY.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. LLS's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call LLS's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact:

Andrea Greif, 914.821.8958

Andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Designers Young Cousin Inspiration Behind Colorful School and Office Supplies That Raise Awareness for Leukemia
2. The Leukemia & Lymphoma Society and the Nations Triathlon Announce New Partnership
3. Sorafenib Slows Growth of Some Leukemias
4. Kidney cancer drug attacks a major type of acute myeloid leukemia
5. Study Gets Closer to Origins of Leukemia
6. Molecules might identify high-risk acute-leukemia patients
7. VIDEO from Medialink and The Leukemia & Lymphoma Society: Saving Lives One Mile at a Time
8. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
9. Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
10. New drug candidate knocks out resistant form of chronic myeloid leukemia
11. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The most common surgical techniques ... of life five years after injury, according to research presented today at the ... Canada. The study followed patients for five years following surgery. , “Orthopaedic surgeons ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid ... cancer that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens ... reoccurrence and relapse. With such a challenging diagnosis that requires immediate action, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Remote ... which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... remote participants for real-time collaboration and immediate decision-making requirements. While never sharing ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... about the introduction of bipartisan House and Senate legislation in support of providing ... Congresswoman Robin Kelly (D-IL) introduced H.R. 2408, the “Protecting Girls’ Access to Education ...
(Date:7/20/2017)... ... July 20, 2017 , ... There’s a lot of confusing lingo out ... are the same thing. But it’s crucial to understand both the differences and similarities ... to Kaixuan Liu, MD, PhD, founder and president of Atlantic Spine Center . ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  Bayer has awarded grants totaling more than ... of its prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. ... Philadelphia and Uniformed Services University of the Health ... winners. Grant recipients were announced last night during a reception ... Congress, Berlin, Germany . ...
Breaking Medicine Technology: